Literature DB >> 30681172

Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma.

Tung-Hung Su1,2, Chun-Jen Liu1,2, Tai-Chung Tseng1,2, Shih-Wan Chou1, Chen-Hua Liu1,2, Hung-Chih Yang1, Shang-Ju Wu3, Pei-Jer Chen1,2,4,5, Ding-Shinn Chen1,2,4,6, Chi-Ling Chen4, Jia-Horng Kao1,2,4,5.   

Abstract

BACKGROUND: Chronic hepatitis B has been linked to lymphoma with contradictory results. AIM: To investigate the association between chronic hepatitis B and lymphoma by using a nationwide population-based cohort.
METHODS: Records of patients diagnosed with chronic hepatitis B (hepatitis B virus [HBV] cohort) or without (non-HBV cohort) during 2004-2007 were retrieved from the Taiwan National Health Insurance Research Database. Age, sex, comorbidities, and medical visits were matched using propensity scores between both cohorts, and they were followed up longitudinally until 2012 to determine any new lymphoma development.
RESULTS: A total of 203 031 patients were included in each cohort with a mean follow-up of 7-9 years. The lymphoma incidence rate was significantly higher in the HBV cohort than in the non-HBV cohort (29.4 vs 15.9 per 100 000 person-years, P < 0.0001). After adjustment for comorbidities and medical visits, HBV infection was found to be an independent risk factor associated with the development of lymphoma (hazard ratio [HR]: 2.07, 95% confidence interval [CI]: 1.76-2.43, P < 0.0001) and non-Hodgkin's lymphoma (HR: 2.18, 95% CI: 1.80-2.65, P < 0.0001); specifically with an increased risk of diffuse large B-cell lymphoma (HR: 2.69, 95% CI: 2.05-3.52, P < 0.0001), other B-cell lymphoma (HR: 3.11, 95% CI: 1.89-5.11, P < 0.0001), and also for multiple myeloma (HR: 1.63, 95% CI: 1.10-2.42, P = 0.016). The association was significant even after excluding lymphoma development within the first year (HR: 2.08, 95% CI: 1.75-2.47, P < 0.0001).
CONCLUSIONS: Chronic hepatitis B is temporally associated with a 2-fold increased risk of lymphoma, particularly with B-cell non-Hodgkin's lymphoma, and also an increased risk for multiple myeloma.
© 2019 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2019        PMID: 30681172     DOI: 10.1111/apt.15132

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  12 in total

1.  Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.

Authors:  Chieh-Lung Cheng; Sheng-Chuan Huang; Jia-Hong Chen; Chao-Hung Wei; Wei-Quan Fang; Tung-Hung Su; Chang-Tsu Yuan; Jia-Hau Liu; Ming-Kai Chuang; Hwei-Fang Tien
Journal:  Oncologist       Date:  2020-04-27

Review 2.  Nonliver Comorbidities in Patients With Chronic Hepatitis B.

Authors:  Mike T Wei; Linda Henry; Mindie H Nguyen
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-10-09

3.  Clinical Analysis and Prognostic Significance of Hepatitis B Virus Infections with Diffuse Large B-Cell Lymphoma.

Authors:  Xindan Kang; Li Bai; Chun Han; Xiaoguang Qi
Journal:  Cancer Manag Res       Date:  2020-04-24       Impact factor: 3.989

4.  Increased risk of lymphoid malignancy in patients with herpes zoster: a longitudinal follow-up study using a national cohort.

Authors:  Hyo Geun Choi; James L Zehnder; Young Kyung Lee; Hyun Lim; Miyoung Kim
Journal:  BMC Cancer       Date:  2019-11-27       Impact factor: 4.430

5.  Primary Hepatic Lymphoma in a Patient with Chronic Hepatitis B.

Authors:  Soumaya Mrabet; Houneida Zaghouani; Sarra Mestiri; Imen Akkari; Elhem Ben Jazia
Journal:  Case Rep Gastroenterol       Date:  2020-11-26

6.  Editorial: Novel Concepts in Mechanisms Modulating HBV Persistence, Pathogenesis, and Oncogenetic Properties.

Authors:  Valentina Svicher; Loredana Sarmati
Journal:  Front Microbiol       Date:  2021-12-24       Impact factor: 5.640

Review 7.  Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia.

Authors:  Alessandro Allegra; Alessandro Tonacci; Caterina Musolino; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 7.561

Review 8.  HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies.

Authors:  Xing Cao; Yafei Wang; Panyun Li; Wei Huang; Xiaojuan Lu; Hongda Lu
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

9.  Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma.

Authors:  Chieh-Lung Cheng; Wei-Quan Fang; Yu-Jen Lin; Chang-Tsu Yuan; Bor-Sheng Ko; Jih-Luh Tang; Hwei-Fang Tien
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-06       Impact factor: 4.322

10.  Evaluation of HBV, HCV, and HIV seroprevalence in patients with plasma cell disorders.

Authors:  Duygu Mert; Alparslan Merdin; Merih Kizil Çakar; Mehmet Sinan Dal; Fevzi Altuntaş
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.